Alphatec Spine Announces Appointment of Donald A. Williams to its Board of Directors
01 Mai 2015 - 2:15PM
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of
Alphatec Spine, Inc., a global provider of spinal fusion
technologies, announced today that its board of directors has
appointed Donald A. Williams as a member of the board of directors,
effectively immediately. Mr. Williams, was a partner at Ernst &
Young for eighteen years and a Partner with Grant Thornton, LLP for
the last seven years. He has served as the lead partner on multiple
initial public offerings, secondary offerings, private and public
debt financings, as well as numerous mergers and acquisitions.
This appointment expands the Alphatec Spine board to 11
directors. Mr. Williams is qualified as an independent director
under the definition established by Nasdaq.
"Don has a solid foundation of financial and business expertise,
and we are delighted that he is joining Alphatec's board of
directors," said Jim Corbett, President and Chief Executive
Officer. "With over 30 years of audit experience across domestic
and international businesses, Don will further strengthen our
Board's breadth of talent and experience. His contributions will be
extremely valuable as we continue to execute on our strategic
objectives."
"I am very excited to be working with Alphatec's experienced
management team and accomplished Board," said Don Williams. "I look
forward to contributing to the Company's execution of both domestic
and international growth and driving future profitability."
Mr. Williams, age 56, is a 35-year veteran of the public
accounting industry, retiring in 2014. Mr. Williams spent 18 years
as an Ernst & Young partner and the last seven years as a
Partner with Grant Thornton. Mr. Williams' career focused on
private and public companies in the technology and life sciences
sectors. During the last seven years at Grant Thornton, he served
as the national leader of Grant Thornton's life sciences practice
and the managing partner of the San Diego Office. He was the lead
partner for both Ernst & Young and Grant Thornton on multiple
initial public offerings; secondary offerings; private and public
debt financings; as well as numerous mergers and acquisitions. From
2001 to 2014, Mr. Williams served on the board of directors and is
past president and chairman of the San Diego Venture Group. Mr.
Williams also has serves as a director of Marina Biotech, Inc.,
Proove Biosciences, Inc. and is on the Board of Advisors of the
Southern Illinois University School of Accountancy.
Further information regarding the Company's appointment of
Donald A. Williams to its board of directors is set forth in a
Current Reports on Form 8-K that was filed with the U.S. Securities
and Exchange Commission (SEC) on May 1, 2015 and is available on
both the SEC's website at www.sec.gov and the Company's website at
www.alphatecspine.com.
About Alphatec Spine
Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec
Holdings, Inc., is a global medical device company that designs,
develops, manufactures and markets spinal fusion technology
products and solutions for the treatment of spinal disorders
associated with disease and degeneration, congenital deformities
and trauma. The Company's mission is to improve lives by delivering
advancements in spinal fusion technologies. The Company and its
affiliates market products in the U.S. and internationally via a
direct sales force and independent distributors.
Additional information can be found at
www.alphatecspine.com.
Forward Looking Statements
This press release may contain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainty. Such statements are
based on management's current expectations and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Alphatec Spine cautions investors that there can be no
assurance that actual results or business conditions will not
differ materially from those projected or suggested in such
forward-looking statements as a result of various factors.
Forward-looking statements include the Company's ability to achieve
profitable growth; the Company's ability to achieve both domestic
and international growth and future profitability. The words
"believe," "will," "should," "expect," "intend," "estimate" and
"anticipate," variations of such words and similar expressions
identify forward-looking statements, but their absence does not
mean that a statement is not a forward-looking statement. Please
refer to the risks detailed from time to time in Alphatec Spine's
SEC reports, including its Annual Report Form 10-K, as well as
other filings on Form 10-Q and periodic filings on Form 8-K.
Alphatec Spine disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events, or otherwise, unless required by
law.
CONTACT: Investor/Media Contact:
Christine Zedelmayer
Investor Relations
Alphatec Spine, Inc.
(760) 494-6610
czedelmayer@alphatecspine.com
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024